These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18374204)

  • 1. Hepatocellular carcinoma and vitamin K.
    Mizuta T; Ozaki I
    Vitam Horm; 2008; 78():435-42. PubMed ID: 18374204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
    Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
    Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical application of vitamin K for hepatocellular carcinoma].
    Mizuta T; Ozaki I
    Clin Calcium; 2007 Nov; 17(11):1693-9. PubMed ID: 17982189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
    Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
    Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study.
    Mizuta T; Ozaki I; Eguchi Y; Yasutake T; Kawazoe S; Fujimoto K; Yamamoto K
    Cancer; 2006 Feb; 106(4):867-72. PubMed ID: 16400650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma.
    Hotta N; Ayada M; Sato K; Ishikawa T; Okumura A; Matsumoto E; Ohashi T; Kakumu S
    Hepatogastroenterology; 2007; 54(79):2073-7. PubMed ID: 18251162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
    Hitomi M; Yokoyama F; Kita Y; Nonomura T; Masaki T; Yoshiji H; Inoue H; Kinekawa F; Kurokohchi K; Uchida N; Watanabe S; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):713-20. PubMed ID: 15703828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection.
    Kakizaki S; Sohara N; Sato K; Suzuki H; Yanagisawa M; Nakajima H; Takagi H; Naganuma A; Otsuka T; Takahashi H; Hamada T; Mori M
    J Gastroenterol Hepatol; 2007 Apr; 22(4):518-22. PubMed ID: 17376044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
    J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.
    Yoshida H; Shiratori Y; Kudo M; Shiina S; Mizuta T; Kojiro M; Yamamoto K; Koike Y; Saito K; Koyanagi N; Kawabe T; Kawazoe S; Kobashi H; Kasugai H; Osaki Y; Araki Y; Izumi N; Oka H; Tsuji K; Toyota J; Seki T; Osawa T; Masaki N; Ichinose M; Seike M; Ishikawa A; Ueno Y; Tagawa K; Kuromatsu R; Sakisaka S; Ikeda H; Kuroda H; Kokuryu H; Yamashita T; Sakaida I; Katamoto T; Kikuchi K; Nomoto M; Omata M
    Hepatology; 2011 Aug; 54(2):532-40. PubMed ID: 21574174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.
    Zhang H; Ozaki I; Hamajima H; Iwane S; Takahashi H; Kawaguchi Y; Eguchi Y; Yamamoto K; Mizuta T
    Oncol Rep; 2011 Jan; 25(1):159-66. PubMed ID: 21109972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hepatocellular carcinoma and vitamin K2].
    Mizuta T; Ozaki I
    Clin Calcium; 2015 Nov; 25(11):1645-51. PubMed ID: 26503869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
    Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
    Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of interferon therapy after curative treatment of hepatocellular carcinoma.
    Kudo M
    Oncology; 2008; 75 Suppl 1():30-41. PubMed ID: 19092270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Akahane T; Asada K; Tsujimoto T; Uemura M; Fukui H
    Oncol Rep; 2006 Jan; 15(1):155-9. PubMed ID: 16328049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials.
    Riaz IB; Riaz H; Riaz T; Rahman S; Amir M; Badshah MB; Kazi AN
    BMC Gastroenterol; 2012 Nov; 12():170. PubMed ID: 23191943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin K2 suppresses proliferation and motility of hepatocellular carcinoma cells by activating steroid and xenobiotic receptor.
    Azuma K; Urano T; Ouchi Y; Inoue S
    Endocr J; 2009; 56(7):843-9. PubMed ID: 19550077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
    J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyprenoic acid in hepatocellular carcinoma.
    Yang CH; Cheng AL
    N Engl J Med; 1996 Nov; 335(19):1460-61; author reply 1461-2. PubMed ID: 8927081
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon for postresection recurrence of hepatocellular carcinoma.
    Mallat DB; El-Serag HB
    Am J Gastroenterol; 2002 Dec; 97(12):3200-2. PubMed ID: 12492213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.